Tarceva, the eye-opening cancer drug with a new drug application pending, typically is regarded as another feather in the cap of Genentech Inc., whose headgear already is festooned with plumage.
Vion Pharmaceuticals Inc. decided to move one lead cancer drug into pivotal trials, while expanding the Phase II trials of its other one. (BioWorld Today)
Sopherion Therapeutics Inc. raised $47 million in a Series B venture financing and, at the same time, entered a licensing deal with Zeneus Pharma Ltd. for Myocet, a breast cancer therapy approved in Europe and Canada. (BioWorld Today)
RSS